---
layout: default
title: Ferric Carboxymaltose
parent: 僅模型預測 (L5)
nav_order: 701
evidence_level: L5
indication_count: 1
---

# Ferric Carboxymaltose
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ferric Carboxymaltose: From Unspecified Original Indication to Bronchitis

## One-Sentence Summary

Ferric carboxymaltose (DrugBank DB08917) is an intravenous iron replacement product; its original approved indication is not documented in the current evidence pack. The TxGNN model predicts a possible association with **Bronchitis** at a very high confidence score, but this prediction is currently supported by **zero clinical trials** and **zero publications**.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in available records (no license data on file) |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.00% |
| Evidence Level | L5 |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, ferric carboxymaltose is an intravenous iron formulation whose established pharmacological role is to replenish iron stores and treat iron deficiency anemia — a mechanism that has no direct relationship to the airway inflammation/infection pathology underlying bronchitis.

The only plausible connection is indirect: patients with chronic bronchitis/COPD frequently have comorbid iron deficiency anemia, and correcting iron deficiency could improve fatigue and exercise tolerance in these patients. This would represent management of a comorbidity rather than treatment of bronchitis itself, and cannot be confirmed without the missing original-indication and MOA data.

Given the very high TxGNN score (0.99) is not corroborated by any clinical trial or literature evidence, this prediction should be treated as a candidate for further screening rather than a validated mechanistic hypothesis — it may reflect model noise or an over-extended association.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This is a model-only prediction (L5) with no supporting clinical trials, literature, or mechanistic data, and a Blocking data gap (missing TFDA label warnings/contraindications) prevents even an initial safety screen (S1).

**To proceed, the following is needed:**
- TFDA/regulatory label data on warnings and contraindications (currently blocking)
- Original approved indication and mechanism of action (MOA) documentation
- At least preliminary clinical or observational evidence linking ferric carboxymaltose to bronchitis or its comorbid presentations
- Drug interaction (DDI) data, which is currently unavailable
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

